false
0001382574
0001382574
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 16, 2026
SCIENTURE
HOLDINGS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
| Delaware |
|
001-39199 |
|
46-3673928 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(I.R.S.
Employer
Identification
No.) |
20
Austin Blvd.
Commack,
NY 11725
(Address
of Principal Executive Offices)
(631)
670-6039
(Registrant’s
Telephone Number)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common stock, par value
$0.00001 per share |
|
SCNX |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
November 16, 2026, Scienture Holdings, Inc. issued a press release announcing certain financial results for the quarter ending September
30, 2026, and other recent operational highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.
The
information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference
in such filing.
Forward
Looking Statements
This
Current Report on Form 8-K contains certain statements that may be deemed to be “forward-looking statements” within the federal
securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are
not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange.
Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements
are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our
beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our management team’s
expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those
products may have in the marketplace, such as Arbli™ and REZENOPY™, and our strategies related to those products. In addition,
any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying
assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “ongoing,” “plan,” “potential,” “predict,” “project,”
“should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that
a statement is not forward-looking. These statements are based on our expectations and involve
risks, uncertainties and other important factors that could cause our actual results, performance or achievements (or entities in which
we have an interest), or industry results, to differ materially from future results, performance or achievements expressed or implied
by such forward-looking statements. Certain factors that could cause our actual future results to differ materially from those discussed
are noted in connection with such statements, but other unanticipated factors (including those beyond our control) could arise. Certain
risks regarding our forward-looking statements are discussed in our filings with the Securities and Exchange Commission, including an
extensive discussion of these risks in our Annual Report on Form 10-K for the year ending December 31, 2025, as amended, and subsequent
Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements which reflect management’s
view only as of the date of this Current Report on Form 8-K. We undertake no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions
or circumstances.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release, dated November 16, 2026. |
| 104 |
|
Cover Page Interactive
Data File (embedded with the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SCIENTURE HOLDINGS, INC. |
| |
|
|
| |
By: |
/s/ Dr. Narasimhan
Mani |
| |
|
Dr. Narasimhan Mani |
| |
|
Co-Chief Executive Officer |
| |
|
|
| Date: November 19, 2026 |
|
|
Exhibit
99.1

SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
Q3
2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million
Arbli™
generated approximately $330,000 and $730,000 of Net Product Revenue for Q3 2026 and the first nine months of 2026 respectively
Initial
Wholesale Shipments of REZENOPY™ Generated Approximately $925,000 of Net Product Revenue Following Its August 2026 Launch
Q3
2026 Gross Profit Increased Approximately 77.5% Year-Over-Year to $1.02 Million
First
Nine Months of 2026 Revenue Increased Approximately 176% Year-Over-Year to $1.65 Million and Gross Profit Increased Approximately 145%
to $1.41 Million
COMMACK,
NY, Nov. 16, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture” or the “Company”),
a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians
and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs,
today provided a business update and reported financial results for the three and nine months ended September 30, 2026.
Third
Quarter 2026 and Nine Months Ended September 30, 2026 Financial Highlights
| ● | Robust
Commercial Execution: Scienture focused on product promotion, branding, market access,
payor coverage expansion and multichannel sales coverage for both Arbli™
and REZENOPY™, which management believes contributed to meaningful sequential
revenue growth and expects will serve as a platform for continued revenue and margin expansion
in the coming quarters. |
| ● | Significant
Sequential Revenue Growth: Revenue increased approximately 265% to $1.25 million in Q3
2026, compared with $343,639 in Q2 2026, exceeding the Company’s preliminary estimate
of approximately $1.22 million announced on October 13, 2026. |
| ● | Strong
Year-Over-Year Revenue Growth: Q3 2026 revenue increased approximately 113% compared
with $590,050 in Q3 2025. Third quarter 2026 revenue consisted entirely of net product sales
of the Company’s two FDA-approved products, Arbli™ and REZENOPY™. |
| ● | Nine-Month
Revenue Growth: Revenue for the first nine months of 2026 increased approximately 176%
to $1.65 million, compared with $600,308 in the corresponding period of 2025, primarily due
to the revenue derived from net product sales of Arbli™ and REZENOPY™. |
| ● | Q3
2026 Gross Profit: Q3 2026 gross profit increased approximately 77.5% to $1.02 million
compared with $574,621 in Q3 2025. Gross margin was approximately 81.3%, reflecting the addition
of REZENOPY™ to the Company’s revenue mix. |
| ● | Nine-Month
Gross Profit: Gross profit increased approximately 145% year-over-year to $1.41 million,
compared to $575,294 in the prior-year period, representing a gross margin of 85.2%, primarily
due to sales of Arbli™ and REZENOPY™. |
| ● | Operating
Loss: Operating loss for the first nine months of 2026 narrowed approximately 8.8% to
$11.9 million, compared with $13.1 million in the corresponding period of 2025. Q3 2026 operating
loss was approximately $5.7 million, compared with approximately $4.4 million in Q3 2025,
and included approximately $0.8 million of FDA fees and an approximately $0.8 million licensing
milestone for REZENOPY™, as well as increased research and development investment
to advance the Company’s product pipeline. |
| ● | Net
Loss: Net loss for the first nine months of 2026 narrowed approximately 8.6% to $12.2
million, compared with $13.4 million in the prior-year period, and net loss per common share
improved to $7.70 from $23.46 during that same period. Q3 2026 net loss was approximately
$6.0 million, compared with approximately $3.6 million in Q3 2025. The prior-year quarter
benefited from a non-cash gain of approximately $2.4 million related to the change in fair
value of a derivative liability. Q3 2026 net loss per common share improved to $3.76 from
$4.76 in the prior-year quarter. Per share amounts reflect the 1-for-25 reverse stock split
effective October 5, 2026. |
| ● | Cash
Position: As of September 30, 2026, the Company had cash, cash equivalents and restricted
cash of approximately $7.8 million compared to approximately $6.7 million of cash and cash
equivalents as of December 31, 2025. |
Key
Operational Highlights in Q3 2026 and Subsequent Events:
| ● | REZENOPY™
Commercial Launch: REZENOPY™ (naloxone hydrochloride) Nasal Spray 10
mg, the highest-dose FDA-approved naloxone nasal spray available in the United States, became
commercially available in August 2026, establishing Scienture’s second commercial-stage
pharmaceutical product. Initial wholesale shipments generated approximately $925,000 of net
product revenue during the third quarter of 2026 and were the primary driver of the Company’s
sequential revenue growth. |
| ● | REZENOPY™
Direct Customer Distribution Agreement: In September 2026, Scienture entered into an
exclusive Sales, Marketing and Distribution Agreement targeting opioid treatment program
clinics and addiction treatment centers across the United States. The agreement provides
access to an established network of approximately 2,000 treatment facilities, expanding REZENOPY™’s
potential commercial reach beyond traditional wholesale distribution channels. |
| ● | Continued
Arbli™ Commercial Expansion: Scienture continued advancing the commercialization
of Arbli™ (losartan oral suspension), the first FDA-approved liquid formulation
of losartan, securing formulary placements at more than ten (10) leading U.S. pediatric hospitals
and academic medical centers boosting institutional access for the product. The Company’s
management believes that product adoption in the Retail and Long-Term Care segments will
continue to grow based on the expanding CMS and Commercial coverage the Company has obtained
for the product. Arbli™ wholesale unit sales increased 74% sequentially
in the third quarter of 2026. |
| ● | First
REZENOPY™ Direct Customer Orders Fulfilled: Subsequent to the third
quarter, Scienture fulfilled and shipped its first orders of REZENOPY™ through
the direct customer channel, marking an important milestone in translating its expanded distribution
infrastructure into commercial activity beyond its initial wholesale shipments. |
Outlook
for rest of 2026 and 2027 and Operational Milestones:
| ● | Breakeven
Operating Income and Profitability: Based on the current sales run rate and the growth
in net product revenue that the Company’s management expects in the upcoming quarters,
the Company’s management believes the business is well poised to achieve the breakeven
Operating Income of $6M and be profitable in 2027. |
| ● | Strong
and continued focus on Commercial Execution: The Company is prioritizing key commercial
activities to continue to ramp our sales growth on Arbli™ and REZENOPY™
for the rest of 2026 and 2027. In this regard, the Company anticipates it will: |
| ○ | Maintain
and build on our commercial infrastructure covering Field and Virtual Promotion, Marketing,
Market Access, Payor Coverage and Patient Assistance Programs. |
| ○ | Leverage
our recent wins in the specialty segments of Pediatrics, Cardiology, Nephrology and Long-Term
Care settings to increase product adoption. |
| ○ | Continue
to expand multi-channel sales across Retail, Institutional and Government customers through
our Wholesale, GPO and Direct purchase programs. |
| ○ | Enhance
CMS (Government) coverage for both products and achieve formulary access into State Medicaid
Preferred Drug Lists and purchase contracts with federal and state agencies. |
| ○ | Bolster
our current commercial coverage available through National Health plans with regional provider
agreements. |
| ○ | Continue
to strengthen our Patient Assistance and Savings Support program and work with all healthcare
providers (prescribers and pharmacists) to assist with product availability and utilization. |
Narasimhan
Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture, commented, “Our third-quarter results
demonstrate the accelerating commercial momentum of Scienture as we begin generating meaningful revenue from two FDA-approved pharmaceutical
products. Revenue increased approximately 265% sequentially to $1.25 million and more than doubled year-over-year. This growth reflects
approximately $925,000 of net revenue from initial wholesale shipments of REZENOPY™ following its August launch, alongside
continued progress with Arbli™. We also generated more than $1.0 million in quarterly gross profit, reflecting what
we see as attractive margins of our expanding commercial portfolio. With much of the commercial infrastructure for both products already
established, we are optimistic of revenue and margin expansion in the coming quarters. We remain focused on expanding market access,
strengthening distribution and accelerating product adoption to drive sustainable revenue growth and achieve our objective of profitability
in 2027.”
Shankar
Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture, stated, “Arbli™ continues to gain commercial
traction, while the successful launch of REZENOPY™ has added a second revenue stream and established our presence in
the opioid overdose treatment market. We are particularly encouraged by the progress of REZENOPY™ beyond traditional
wholesale distribution, including the fulfillment of our first orders through a dedicated direct customer channel that provides access
to approximately 2,000 opioid treatment clinics and addiction treatment centers nationwide. Building on this momentum, we are actively
pursuing additional distribution relationships, particularly within government markets, where we see opportunities to expand product
access, diversify revenue streams and establish a scalable commercial platform to support long-term growth.”
About
Arbli™
Arbli™
is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first
and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf
life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than
six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic
nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™
provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™
provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded
losartan prescriptions. Arbli™ has three issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™
is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle
as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the
date of manufacture when stored at room temperature.
INDICATION
Arbli™
is an angiotensin II receptor blocker (ARB) indicated for:
| ● | Treatment
of hypertension, to lower blood pressure in adults and children greater than 6 years old.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily
strokes and myocardial infarctions. |
| ● | Reduction
of the risk of stroke in patients with hypertension and left ventricular hypertrophy. |
| ● | Treatment
of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with
type 2 diabetes and a history of hypertension. |
IMPORTANT
SAFETY INFORMATION
| ● | Do
not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™
as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury
and death to the developing fetus. Arbli™ can cause fetal harm when
administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during
the second and third trimesters of pregnancy reduces fetal renal function and increases fetal
and neonatal morbidity and death. |
| ● | Do
not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid
use of aliskiren with Arbli™ in patients with renal impairment (GFR <60
mL/min). |
| ● | Do
not administer Arbli™ in patients with severe hepatic impairment. Arbli™
has not been studied in patients with severe hepatic impairment. |
| ● | The
most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness,
upper respiratory infection, nasal congestion, and back pain. |
You
are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also contact Scienture at 1-833-754-4917.
Please
see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About
Hypertension
Hypertension
(high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According
to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million
people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher.
Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk
of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and
drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic
blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About
REZENOPY™
REZENOPY™
(naloxone hydrochloride) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid
overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate
administration as emergency therapy in settings where opioids may be present.
REZENOPY™
nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.
IMPORTANT
SAFETY INFORMATION
REZENOPY™
(naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid
overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate
administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.
Important
Safety Information
| ● | Contraindications:
REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive
to naloxone hydrochloride or to any of the other ingredients. |
| ● | Warnings
and Precautions: |
| ● | Risk
of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative
to the opioid, keep the patient under continued surveillance and administer additional doses
as necessary while awaiting emergency medical assistance. |
| ● | Risk
of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory
depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine
and pentazocine, may be incomplete. Larger or repeat doses may be required. |
| ● | Precipitation
of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid
withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and
properly treated. Monitor for the development of opioid withdrawal. |
| ● | Risk
of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result
in adverse cardiovascular effects. These events have primarily occurred in patients who had
pre-existing cardiovascular disorders or received other drugs that may have similar adverse
cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting
after use of naloxone hydrochloride. |
| ● | Adverse
Reactions: The following adverse reactions were observed in a REZENOPY™
nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia. |
For
complete product information, including Patient Information, please refer to the full Prescribing Information.
About
Scienture Holdings, Inc.
SCIENTURE
HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company
focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market
needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals
who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare
systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and
channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary
Statements Regarding Forward-Looking Statements
This
press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities
laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking
statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,
our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management
team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we have launched
or may launch, the success those products may have in the marketplace, such as Arbli™ and REZENOPY™,
our commercial, distribution and market access strategies related to those products, our expectations regarding future revenue, gross
margin, and profitability, and our future financial condition and results of operations. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,”
“potential,” “predict,” “project,” “should,” or the negative of these terms or other
similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements
are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance
to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place
undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties, including our
reliance on third-party licensors, manufacturers and distributors; our dependence on a limited number of wholesale distributors for substantially
all of our product sales; variability in quarterly revenue resulting from wholesaler ordering patterns and gross-to-net adjustments;
the market adoption of, and the availability of payor coverage and formulary access for, Arbli™ and REZENOPY™;
our ability to enter into, and realize the anticipated benefits of, distribution agreements and other commercial arrangements; our ability
to achieve profitability; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution
caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability
to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property
rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated
difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as
amended, and subsequent reports filed with the Securities and Exchange Commission.
Forward-looking
statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided
by law.
Contact:
SCIENTURE
HOLDINGS, INC.
20
Austin Blvd
Commack,
NY 11725
Email:
IR@Scienture.com
Scienture
Holdings, Inc. formerly TRxADE HEALTH, INC.
Condensed
Consolidated Balance Sheets
As
of September 30, 2026 and December 31, 2025
(Unaudited)
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| ASSETS | |
| | | |
| | |
| Current assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 4,747,439 | | |
$ | 6,662,008 | |
| Accounts receivable, net | |
| 2,220,101 | | |
| 731,328 | |
| Inventory | |
| 998,109 | | |
| 213,408 | |
| Prepaid expenses | |
| 382,187 | | |
| 262,278 | |
| Subscription receivable | |
| 484,995 | | |
| - | |
| Deferred offering costs | |
| - | | |
| 47,384 | |
| Total current assets | |
| 8,832,831 | | |
| 7,916,406 | |
| Restricted cash | |
| 3,030,085 | | |
| - | |
| Property, plant and equipment, net | |
| 14,500 | | |
| 15,500 | |
| Notes receivable | |
| 5,000,000 | | |
| 5,000,000 | |
| Interest receivable | |
| 531,250 | | |
| 250,000 | |
| Intangible assets, net | |
| 69,611,525 | | |
| 70,973,064 | |
| Operating lease right-of-use assets | |
| 164,115 | | |
| 23,360 | |
| Total assets | |
$ | 87,184,306 | | |
$ | 84,178,330 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 4,142,469 | | |
$ | 1,443,266 | |
| Accrued liabilities | |
| 1,938,526 | | |
| 657,034 | |
| Operating lease liability - current | |
| 21,508 | | |
| 24,137 | |
| Warrant liability | |
| 46,124 | | |
| 10,914 | |
| Note payable, net of debt discount - current portion | |
| 1,626,602 | | |
| - | |
| Development agreement liability - current portion | |
| 285,000 | | |
| 600,000 | |
| Total current liabilities | |
| 8,060,229 | | |
| 2,735,351 | |
| Note payable, net of debt discount | |
| 9,199,675 | | |
| - | |
| Lease Liability | |
| 143,223 | | |
| - | |
| Development agreement liability | |
| - | | |
| 285,000 | |
| Deferred tax liability | |
| 11,037,595 | | |
| 11,037,595 | |
| Total liabilities | |
| 28,440,722 | | |
| 14,057,946 | |
| | |
| | | |
| | |
| Commitments and contingencies (Note 13) | |
| | | |
| | |
| | |
| | | |
| | |
| Stockholders’ equity: | |
| | | |
| | |
| | |
| | | |
| | |
| Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both September 30, 2026 and December 31, 2025 | |
| - | | |
| - | |
| Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both September 30, 2026 and December 31, 2025 | |
| - | | |
| - | |
| Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both September 30, 2026 and December 31, 2025 | |
| - | | |
| - | |
| Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both September 30, 2026 and December 31, 2025 | |
| - | | |
| - | |
| | |
| | | |
| | |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 1,787,953 and 1,625,232 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively 75,262 and 40,600 shares unvested as of September 30, 2026 and December 31, 2025, respectively | |
| 17 | | |
| 16 | |
| Additional paid-in capital | |
| 151,528,886 | | |
| 150,671,605 | |
| Accumulated deficit | |
| (92,785,319 | ) | |
| (80,551,237 | ) |
| Total stockholders’ equity | |
| 58,743,584 | | |
| 70,120,384 | |
| Total liabilities and stockholders’ equity | |
$ | 87,184,306 | | |
$ | 84,178,330 | |
Scienture
Holdings, Inc. formerly TRxADE HEALTH, INC.
Condensed
Consolidated Statements Of Operations
For
the Three and Nine Months Ended September 30, 2026 and 2025
(Unaudited)
| | |
Three Months Ended | | |
Nine Months Ended | |
| | |
September 30, | | |
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Revenues | |
$ | 1,254,577 | | |
$ | 590,050 | | |
$ | 1,654,541 | | |
$ | 600,308 | |
| Cost of sales | |
| 234,628 | | |
| 15,429 | | |
| 244,963 | | |
| 25,014 | |
| Gross profit | |
| 1,019,949 | | |
| 574,621 | | |
| 1,409,578 | | |
| 575,294 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| Wage and salary expense | |
| 422,234 | | |
| 251,747 | | |
| 1,253,653 | | |
| 1,721,554 | |
| Professional fees | |
| 1,831,332 | | |
| 1,320,845 | | |
| 3,727,636 | | |
| 1,943,458 | |
| Accounting and legal expense | |
| 167,742 | | |
| 1,018,737 | | |
| 611,735 | | |
| 1,871,245 | |
| Technology expense | |
| 3,900 | | |
| 9,756 | | |
| 26,802 | | |
| 92,784 | |
| General and administrative | |
| 2,930,405 | | |
| 2,165,398 | | |
| 4,374,059 | | |
| 6,449,110 | |
| Research and development | |
| 1,387,842 | | |
| 169,344 | | |
| 3,348,431 | | |
| 1,587,572 | |
| Total operating expenses | |
| 6,743,455 | | |
| 4,935,827 | | |
| 13,342,316 | | |
| 13,665,723 | |
| Operating loss | |
| (5,723,506 | ) | |
| (4,361,206 | ) | |
| (11,932,738 | ) | |
| (13,090,429 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Non-operating income (expense): | |
| | | |
| | | |
| | | |
| | |
| Change in fair value of warrant liability | |
| (46,124 | ) | |
| 59,203 | | |
| (35,214 | ) | |
| 781,311 | |
| Change in fair value of derivative liability | |
| - | | |
| 2,356,428 | | |
| - | | |
| 2,296,834 | |
| Gain (loss) on conversion of note payable | |
| - | | |
| 43,200 | | |
| - | | |
| (53,446 | ) |
| Gain (loss) on disposition of subsidiaries | |
| - | | |
| 97,324 | | |
| - | | |
| (288,204 | ) |
| Interest income | |
| 138,130 | | |
| 1,120 | | |
| 418,621 | | |
| 89,710 | |
| Interest expense | |
| (377,947 | ) | |
| (1,803,430 | ) | |
| (684,751 | ) | |
| (3,127,707 | ) |
| Total non-operating expense | |
| (285,941 | ) | |
| 753,845 | | |
| (301,344 | ) | |
| (301,502 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Benefit (provision) for income taxes | |
| - | | |
| - | | |
| - | | |
| - | |
| Net loss | |
$ | (6,009,447 | ) | |
$ | (3,607,361 | ) | |
$ | (12,234,082 | ) | |
$ | (13,391,931 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss per common share | |
| | | |
| | | |
| | | |
| | |
| Basic | |
$ | (3.76 | ) | |
$ | (4.76 | ) | |
$ | (7.70 | ) | |
$ | (23.46 | ) |
| Diluted | |
$ | (3.76 | ) | |
$ | (4.76 | ) | |
$ | (7.70 | ) | |
$ | (23.46 | ) |
| Weighted average common shares outstanding | |
| | | |
| | | |
| | | |
| | |
| Basic | |
| 1,597,160 | | |
| 758,306 | | |
| 1,588,854 | | |
| 570,796 | |
| Diluted | |
| 1,597,160 | | |
| 758,306 | | |
| 1,588,854 | | |
| 570,796 | |